Blog
About

29
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

      Blood

      metabolism, Antigens, CD19, Transplantation, Homologous, immunology, T-Lymphocytes, methods, Stem Cell Transplantation, Protein Engineering, Molecular Sequence Data, cytology, Leukocytes, Mononuclear, Humans, Histocompatibility Antigens Class I, HEK293 Cells, Gene Transfer Techniques, Embryonic Stem Cells, Electroporation, genetics, Deoxyribonucleases, Cytotoxicity, Immunologic, Cell Differentiation, Base Sequence, Zinc Fingers

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Long-term engraftment of allogeneic cells necessitates eluding immune-mediated rejection, which is currently achieved by matching for human leukocyte antigen (HLA) expression, immunosuppression, and/or delivery of donor-derived cells to sanctuary sites. Genetic engineering provides an alternative approach to avoid clearance of cells that are recognized as "non-self" by the recipient. To this end, we developed designer zinc finger nucleases and employed a "hit-and-run" approach to genetic editing for selective elimination of HLA expression. Electro-transfer of mRNA species coding for these engineered nucleases completely disrupted expression of HLA-A on human T cells, including CD19-specific T cells. The HLA-A(neg) T-cell pools can be enriched and evade lysis by HLA-restricted cytotoxic T-cell clones. Recognition by natural killer cells of cells that had lost HLA expression was circumvented by enforced expression of nonclassical HLA molecules. Furthermore, we demonstrate that zinc finger nucleases can eliminate HLA-A expression from embryonic stem cells, which broadens the applicability of this strategy beyond infusing HLA-disparate immune cells. These findings establish that clinically appealing cell types derived from donors with disparate HLA expression can be genetically edited to evade an immune response and provide a foundation whereby cells from a single donor can be administered to multiple recipients.

          Related collections

          Author and article information

          Journal
          23741009
          3750336
          10.1182/blood-2013-03-478255

          Comments

          Comment on this article